Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest

References

• Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):1–10. doi: 10.2340/00015555-0770.
   Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi: 10.1056/NEJMra0804595.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):569–579. doi: 10.1016/j.rdc.2015.07.003.
   PubMed Web of Science ®Google Scholar
• Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128. doi: 10.1111/bjd.13272.
   PubMed Web of Science ®Google Scholar
• Reich K, Krüger K, Mössner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040–1047. doi: 10.1111/j.1365-2133.2008.09023.x.
   PubMed Web of Science ®Google Scholar
• Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–636. doi: 10.1111/j.1365-2133.2009.09593.x.
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2(1):16082. doi: 10.1038/nrdp.2016.82.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gieler U, Linder D, et al. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010;24(9):989–1004. doi: 10.1111/j.1468-3083.2010.03705.x.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613. doi: 10.4049/jimmunol.1800013.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Kyntheum summary of product characteristics. 2017. (cited 2023 Sep12). Available from: https://www.ema.europa.eu/documents/product-information/kyntheum-epar-product-information_en.pdf.
   Google Scholar
• Valeant Pharmaceuticals Inc. Prescribing information: SILIQTM (brodalumab) injection for subcutaneous use. 2017. (cited 2023 Sep12). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
   Google Scholar
• Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–3836. doi: 10.4049/jimmunol.1301737.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/NEJMoa1503824.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi: 10.1111/bjd.14493.
   PubMed Web of Science ®Google Scholar
• Reich K, Hansen JB, Puig L, et al. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. J Eur Acad Dermatol Venereol. 2021;35(10):2034–2044. doi: 10.1111/jdv.17433.
   PubMed Web of Science ®Google Scholar
• Warren RB, Hansen JB, Reich K, et al. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2021;35(2):450–457. doi: 10.1111/jdv.16816.
   PubMed Web of Science ®Google Scholar
• Reich K, Iversen L, Puig L, et al. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2022;36(8):1275–1283. doi: 10.1111/jdv.18068.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306. doi: 10.1056/NEJMoa1315231.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80(2):185–193. doi: 10.1136/annrheumdis-2019-216835.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Dapavo P, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35(3):693–700. doi: 10.1111/jdv.16931.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299–1310. doi: 10.1080/14712598.2021.1941862.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Angelakopoulos C, Apalla Z, et al. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: results from an interim analysis of the BrIDGE study. Dermatol Ther. 2022;35(12):e15886. doi: 10.1111/dth.15886.
   PubMed Web of Science ®Google Scholar
• Tampouratzi E, Papakonstantis M, Katsantonis J, et al. Clinical evidence on the use of brodalumab for the treatment of ­psoriasis in Greece: experience from clinical practice of four tertiary hospitals. Dermatol Ther. 2022;35:e15532.
   PubMedGoogle Scholar
• Papadavid E, Zafeiriou E, Georgiou S, et al. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece. J Dermatolog Treat. 2022;33(7):3053–3059. doi: 10.1080/09546634.2022.2110836.
   PubMed Web of Science ®Google Scholar
• Augustin M, Spehr C, Radtke MA, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges. 2014;12(1):48–57. doi: 10.1111/ddg.12233.
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from the German psoriasis registry PsoBest. Arch Dermatol Res. 2015;307(10):875–883. doi: 10.1007/s00403-015-1593-8.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839.
   PubMedGoogle Scholar
• Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194–199. doi: 10.1159/000083509.
   PubMed Web of Science ®Google Scholar
• Basra MK, Fenech R, Gatt RM, et al. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035. doi: 10.1111/j.1365-2133.2008.08832.x.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301(8):561–571. doi: 10.1007/s00403-009-0928-8.
   PubMed Web of Science ®Google Scholar
• ICH. Medical Dictionary for Regulatory Activities: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (cited 2023 Sep 14 September). Available from: https://www.ich.org/page/meddra.
   Google Scholar
• van Houwelingen HC, van de Velde CJ, Stijnen T. Interim analysis on survival data: its potential bias and how to repair it. Stat Med. 2005;24(18):2823–2835. doi: 10.1002/sim.2248.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, Open-Label, phase II study. Am J Clin Dermatol. 2019;20(6):863–871. doi: 10.1007/s40257-019-00466-2.
   PubMed Web of Science ®Google Scholar
• Kokolakis G, Vadstrup K, Hansen JB, et al. Brodalumab is associated with high rates of complete clearance and quality of life improvement: a subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis. Dermatology. 2022;238(4):620–629. doi: 10.1159/000520290.
   PubMed Web of Science ®Google Scholar
• Karczewski J, Poniedziałek B, Rzymski P, et al. Factors affecting response to biologic treatment in psoriasis. Dermatol Ther. 2014;27(6):323–330. doi: 10.1111/dth.12160.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179(2):320–328. doi: 10.1111/bjd.16464.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158. doi: 10.1111/jdv.13611.
   PubMed Web of Science ®Google Scholar